1. Please check and comment entries here.
Table of Contents

    Topic review

    Imaging Techniques in CKD-MBD


    Standard radiological imaging is generally used for the diagnosis of fracture or pseudo-fractures, vascular calcifications and other features of CKD-MBD. However, bone fractures can also be diagnosed using computed tomography (CT) scan, magnetic resonance (MR) imaging and vertebral fracture assessment (VFA). Fracture risk can be predicted by bone densitometry using dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QTC) and peripheral quantitative computed tomography (pQTC), quantitative ultrasound (QUS) and most recently magnetic resonance micro-imaging. 

    1. Introduction

    The mineral and bone disorders associated with chronic kidney disease (CKD) are often progressive in earlier stages of CKD but remain clinically silent until stages G3b-G4 (estimated glomerular filtration rate (eGFR) 30 to 44 or 15 to 29 mL/min/1.73 m2 of body surface). Serum bone biomarkers are the earliest indicators of mineral bone diseases (MBD) during CKD progression, starting with decreased circulating alpha klotho levels and an increase of serum fibroblast growth factor 23 (FGF23). As CKD progresses, circulating 1,25 dihydroxyvitamin D values decrease, serum parathyroid hormone (PTH) rises and subsequent detectable alterations of serum calcium and phosphate metabolism occur [1]. The prevalence of CKD is still growing above other life-style diseases, affecting over 850 million people worldwide [2], and as patients get older and have a longer life expectation, the prevalence of CKD rises, together with the incidence of MBD. The combination of CKD-related low or high rates of bone turnover, mineralization defects and reduced bone mass has been termed renal osteodystrophy. However, seen more globally, bone disease in CKD is the sum of CKD-specific risk factors, which are in turn dependent on CKD progression, together with age- or sex-related bone loss. These complex and interacting changes to bone require careful evaluation, including using imaging techniques [3].

    2. Characteristics of Bone Structure

    Eighty percent of the human skeleton is composed of cortical bone and the other 20% is trabecular bone [4]. The proportion of cortical and trabecular bone differs according to each skeletal site, so the information provided by imaging should be considered in the light of this distribution. When evoked by pain, imaging techniques offer guidance towards the type of CKD-MBD and may reveal prevalent fractures or pseudo-fractures. Imaging can also provide information on bone fragility and monitor changes after a medical intervention.

    Due to its higher proportion of cortical bone, imaging of the proximal femur or femoral neck sites reflect more accurately cortical BMD, which is correlated to femoral strength. With age, cortical bone resorption accelerates, resulting in cortical thinning and increased cortical porosity. Chronic metabolic changes such as high PTH in CKD patients further enhance these features. 

    3. Bone and Soft Tissue Imaging

    Plain radiographs do not quantify bone loss, and consequently other techniques

    Table 1. Different imaging techniques, underlying lesion mechanisms and localization and CKD stage in which it is mostly used.

    Type Mechanism Skeletal Site Type of Bone Disease CKD Stage
    Plain Radiography Bone resorption lesions
    Bone cysts
    Sub-periosteal Subchondral
    Extra-skeletal calcifications
    All skeleton
    Secondary Hyperparathyroidism
    Multiple Myeloma
    Calcific Uremic Arteriolopathy
    DXA Areal BMD measurements Hip, distal radius, lumbar spine, whole body Osteopenia
    Vertebral Assessment Fracture (VAF) Vertebral deformities Spine Vertebral fractures All
    HR-pQCT Trabecular architecture Volumetric BMD Hip, distal radius, distal tibia Secondary Hyperparathyroidism All and research
    Bone Scintigraphy Tracer accumulation occurs in osteoblastic activity, and to a lesser extent, skeletal vascularity;
    Systemic amyloid burden;
    Whole body Osteoarthritis
    Metabolic Bone Disease:
    -Hyperparathyroidism and vitamin D deficiency
    Rare Osteoarticular Diseases: Sarcoidosis with bone involvement;
    Amyloidosis: 123I SAP scintigraphy if available—assess amyloid deposition in liver, spleen, kidneys, adrenals, localized soft tissue deposits and bones
    131I-β2M amyloidosis
    MRI Cortical porosity
    Marrow fat content and composition
    Marrow perfusion, and molecular diffusion
    Distal radius, distal tibia,
    calcaneus, hip, spine
    Whole skeleton
    Secondary Hyperparathyroidism Research
    PET Bone formation rate, osteoclast, osteoblast, erosion and mineralized surfaces Lumbar region Low or high bone turnover disease All
    US Cortical deterioration Tibia Secondary Hyperparathyroidism Research

    DXA, Dual-energy X-ray Absorptiometry; BMD, Bone Mineral Density; HR-pQCT, High Resolution-peripheral Quantitative Computerized Tomography; MRI, Magnetic Resonance Image; PET, Positron Energy Tomography; US, Ultrasounds Velocity.

    have been developed such as radiographic absorptiometry, DXA, QUS, QCT, pQCT, HR-pQCT and more recently quantitative magnetic resonance imaging (MRI). These methods facilitate an analytic approach and may improve the distinction between differing bone pathologies and fracture prediction in patients with CKD. The main limitation is the affordability of some methods, and the need for validation in CKD populations before being suggested its use in clinical practice (Table 1).

    3.1. Conventional Radiography

    Radiography is widely available, affordable and the most used radiological imaging method to characterize bone disease, including specific features of CKD (Figure 1).  Plain x-rays can provide information about high bone remodeling and mineralization failure. 

    Diagnostics 11 00772 g003 550

    Figure 1. Standard Skeletal Radiography images: (A) Left lower arrow, sub periosteal resorption of the distal phalanx of the middle finger, and at the intermediate phalanx of the index finger as indicated by the right upper arrow in a hemodialysis patient, virtually pathognomonic of severe secondary hyperparathyroidism. (B) Image of a “brown tumor” at the distal radius metaphyseal as indicated by the arrow. It is a well-limited lytic lesion with endosteal scalloping, one of the possible manifestations of severe secondary hyperparathyroidism. (C) Periarticular calcifications of the glenohumeral ligaments, appearing as cloud-like densities that diffuse into the adjacent tenosynovial tissues. (D) “Salt and pepper” aspect of the calvaria seen as well-defined lucencies suggesting bone resorption. (E) Lateral spine X-ray can be used to assess vertebral fracture in a hemodialysis patient. (F) Multiple oblique spiral fractures in the proximal, middle and distal third of the humerus in a hemodialysis patient with osteomalacia.

    Osteosclerosis is an additional feature of SHPT occurring predominantly in the axial skeleton and often detected on lateral lumbar spine radiographs [5] affecting the superior and inferior endplates (“rugger jersey spine”), this is mostly due to deposition of mineral crystals and calcification in the collagenous portion of the endplates. Conventional x-rays also identify extra-skeletal calcifications. Plain radiographs may also reveal the now rare entity of amyloid arthropathy, characterized by subchondral erosions [6], often located in periarticular bone and at the site of ligamentous insertions [7]

    3.2. Dual-Energy X-ray Absorptiometry

    DXA is valuable for the quantification of BMD and the evaluation of fracture risk [8]. Axial measurement of the lumbar spine and hip (central DXA) using a stationary scan table is the most common modality. The technique produces little radiation and obtains a rapidly acquired two-dimensional (areal) image with good resolution.

    3.3. DXA-Derived Trabecular Bone Score (TBS)

    The trabecular bone score (TBS) is another available and validated tool that evaluates trabecular microarchitecture through BMD measures obtained at the lumbar spine by DXA [9]. An advantage of TBS is that overlapping vascular calcifications and degenerative changes do not interfere with its measurement. Patients on hemodialysis have a significantly lower TBS than controls without osteoporosis, and this is independent of BMD or other covariates (1.15 ± 0.181 vs. 1.32 ± 0.123, p = 0.001, respectively) [10].

    3.4. Radiographic Absorptiometry (RA)

    DXA and TBS techniques may not be widely available because of their relatively high capital cost and lack of expertise in many non-industrialized countries. In this case, RA could be an alternative approach for the evaluation of BMD. RA is both rapid and inexpensive because it does not require dedicated equipment. RA measures the second metacarpal mid-shaft BMD by using X-ray radiographs, combined with digital image processing (DIP) and a computed X-ray densitometer to improve the precision and accuracy [11][12]. Several studies have shown that RA-based BMD assessment can reliably be used for the estimation of fracture risk in post-menopausal women [13]. In hemodialysis patients, a recent study in 456 hemodialysis patients demonstrate that lower metacarpal BMD measured by DIP-assisted RA predicts the risk of osteoporotic fractures [14].

    3.5. Quantitative Computerized Tomography

    QCT allows in vivo assessment of trabecular architecture, volumetric BMD and bone size, from which BMD can be estimated. QCT also provides a functional approach to bone densitometry by measuring bone strength through biomechanical parameters. QCT imaging can disclose pathological fractures and delineate joint lesions related to amyloidosis. As QCT uses a high radiation dose in a small field of view, it can also be used to monitor bone structural changes over time, disease progression and treatment efficacy. However, In vivo applications are limited. Peripheral QCT (pQCT) limits radiation to the tibia and distal radius.

    3.6. High Resolution-Peripheral Quantitative Computerized Tomography (HR-pQCT)

    HR-pQCT provides excellent spatial resolution, differentiating trabecular from cortical bone and using a lower radiation dose (Figure 2).

    Diagnostics 11 00772 g005 550

    Figure 2. High resolution-peripheral quantitative computerized tomography (HR-pQCT): Analysis of trabecular and cortical microarchitecture proximally and distally at ulnar and radial level. 

    3.7. Magnetic Resonance Imaging (MRI)

    Whereas HR-pQCT is more limited to peripheral skeleton regions like the radius and tibia, MRI can also image sites such as the proximal femur, but usually with lower spatial resolution (Figure 3).

    Diagnostics 11 00772 g006 550

    Figure 3. Magnetic Resonance Imaging: (A) Bilateral metaphyseal femoral fractures distal to the lesser trochanter with reactional associated bone edema in a hemodialysis patient with osteomalacia. (B) Osteoporotic lumbar spine compression fracture at T11, T12, L1, L3 and L4 vertebral body that is hyperintense on T2 and shows vivid contrast enhancement with paravertebral soft tissue edema.

    3.8. Other Imaging Techniques

    Nuclear imaging techniques based on radiotracer accumulation can be used for determining the extent, progression and for monitoring of systemic diseases. Positron energy tomography (PET) scanning is a noninvasive quantitative imaging technique that estimates bone turnover [15] through the measurement of fluoride activity in the bone. Bone formation rate [16], osteoclast, osteoblast, erosion and mineralized surfaces correlate with the tracer intake. PET was superior to PTH in differentiating patients with low from high bone turnover in 26 hemodialysis patients [15]. Ultrasound (US) velocity at the tibia was found to be significantly lower in 42 hemodialysis patients when compared to the control group indicating cortical deterioration related to the degree of SHPT [17]. More studies are needed to validate US as a screen and diagnosis tool regarding the evaluation of CKD-MBD.

    Finally, HR-MRI, Raman spectroscopy, Fourier transform infrared spectroscopy, and quantitative backscatter electron imaging [18] are also currently being used in research studies. To date, none of these techniques can be recommended for use in clinical care.

    The entry is from 10.3390/diagnostics11050772


    1. Isakova, T. An Introduction to PTH, Phosphate and Vitamin D: Current Issues and Concerns. Semin. Dial. 2015, 28, 563.
    2. Jager, K.J.; Kovesdy, C.; Langham, R.; Rosenberg, M.; Jha, V.; Zoccali, C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019, 96, 1048–1050.
    3. Covic, A.; Vervloet, M.; Massy, Z.A.; Torres, P.U.; Goldsmith, D.; Brandenburg, V.; Mazzaferro, S.; Evenepoel, P.; Bover, J.; Apetrii, M.; et al. Bone and mineral disorders in chronic kidney disease: Implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 2018, 6, 319–331.
    4. Clarke, B. Normal Bone Anatomy and Physiology. Clin. J. Am. Soc. Nephrol. 2008, 3 (Suppl. 3), S131–S139.
    5. Jevtic, V. Imaging of renal osteodystrophy. Eur. J. Radiol. 2003, 46, 85–95.
    6. Siakallis, L.; Tziakouri-Shiakalli, C.; Georgiades, C.S. Erratum to “Amyloidosis: Review and Imaging Findings” [Seminars in Ultrasound, CT, and MRI 2014;35(3):225-239]. Semin. Ultrasound CT MRI 2015, 36, 216.
    7. Kiss, E.; Keusch, G.; Zanetti, M.; Jung, T.; Schwarz, A.; Schocke, M.; Jaschke, W.; Czermak, B.V. Dialysis-Related Amyloidosis Revisited. Am. J. Roentgenol. 2005, 185, 1460–1467.
    8. Cummings, S.R.; Bates, D.; Black, D.M. Clinical use of bone densitometry: Scientific review. JAMA 2002, 288, 1889–1897.
    9. Silva, B.C.; Leslie, W.D.; Resch, H.; Lamy, O.; Lesnyak, O.; Binkley, N.; McCloskey, E.V.; Kanis, J.A.; Bilezikian, J.P. Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. J. Bone Miner. Res. 2014, 29, 518–530.
    10. Yavropoulou, M.P.; Vaios, V.; Pikilidou, M.; Chryssogonidis, I.; Sachinidou, M.; Tournis, S.; Makris, K.; Kotsa, K.; Daniilidis, M.; Haritanti, A.; et al. Bone Quality Assessment as Measured by Trabecular Bone Score in Patients With End-Stage Renal Disease on Dialysis. J. Clin. Densitom. 2017, 20, 490–497.
    11. Hayashi, Y.; Yamamoto, K.; Fukunaga, M.; Ishibashi, T.; Takahashi, K.; Nishii, Y. Assessment of bone mass by image analysis of metacarpal bone roentgenograms: A quantitative digital image processing (DIP) method. Radiat. Med. 1990, 8, 173–178.
    12. Ross, P.D. Radiographic absorptiometry for measuring bone mass. Osteoporos. Int. 1997, 7 (Suppl. 3), S103–S107.
    13. Dey, A.; McCloskey, E.V.; Taube, T.; Cox, R.; Pande, K.C.; Ashford, R.U.; Forster, M.; de Takats, D.; Kanis, J.A. Metacarpal Morphometry Using a Semi-automated Technique in the Assessment of Osteoporosis and Vertebral Fracture Risk. Osteoporos. Int. 2000, 11, 953–958.
    14. Nakagawa, Y.; Komaba, H.; Hamano, N.; Wada, T.; Hida, M.; Suga, T.; Kakuta, T.; Fukagawa, M. Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. Kidney Int. 2020, 98, 970–978.
    15. Aaltonen, L.; Koivuviita, N.; Seppänen, M.; Tong, X.; Kröger, H.; Löyttyniemi, E.; Metsärinne, K. Correlation between 18F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone 2020, 134, 115267.
    16. Messa, C.; Goodman, W.G.; Hoh, C.K.; Choi, Y.; Nissenson, A.R.; Salusky, I.B.; Phelps, M.E.; Hawkins, R.A. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry. J. Clin. Endocrinol. Metab. 1993, 77, 949–955.
    17. Wittich, A.; Vega, E.; Casco, C.; Marini, A.; Forlano, C.; Segovia, F.; Nadal, M.; Mautalen, C. Ultrasound Velocity of the Tibia in Patients on Hemodialysis. J. Clin. Densitom. 1998, 1, 157–163.
    18. Goldenstein, P.T.; Jamal, S.A.; Moyses, R.M. Fractures in chronic kidney disease: Pursuing the best screening and management. Curr. Opin. Nephrol. Hypertens. 2015, 24, 317–323.